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Ribosomopathies are a class of diseases caused by mutations that
affect the biosynthesis and/or functionality of the ribosome.
Although they initially present as hypoproliferative disorders,
such as anemia, patients have elevated risk of hyperproliferative
disease (cancer) by midlife. Here, this paradox is explored using
the rpL10-R98S (uL16-R98S) mutant yeast model of the most
commonly identified ribosomal mutation in acute lymphoblastic
T-cell leukemia. This mutation causes a late-stage 60S subunit
maturation failure that targets mutant ribosomes for degradation.
The resulting deficit in ribosomes causes the hypoproliferative
phenotype. This 60S subunit shortage, in turn, exerts pressure on
cells to select for suppressors of the ribosome biogenesis defect,
allowing them to reestablish normal levels of ribosome production
and cell proliferation. However, suppression at this step releases
structurally and functionally defective ribosomes into the transla-
tionally active pool, and the translational fidelity defects of these
mutants culminate in destabilization of selected mRNAs and short-
ened telomeres. We suggest that in exchange for resolving their
short-term ribosome deficits through compensatory trans-acting
suppressors, cells are penalized in the long term by changes in gene
expression that ultimately undermine cellular homeostasis.
frameshifting | L10/uL16
Ribosomopathies are a family of congenital diseases that arelinked to genetic defects in ribosomal proteins or ribosome
biogenesis factors. They are characterized by pleiotropic abnor-
malities that include birth defects, heart and lung diseases, con-
nective tissue disorders, anemia, ataxia, and mental retardation
(reviewed in ref. 1). Although each ribosomopathy presents a
unique pathological spectrum, the inherited forms are char-
acterized by bone marrow failure and anemia early in life, fol-
lowed by elevated cancer risk by middle age. For example,
although childhood anemia is one of the cardinal symptoms of
the genetically inherited disease Diamond–Blackfan anemia,
these patients have a fivefold higher lifetime risk of cancer than
the general population and a 30- to 40-fold higher risk of de-
veloping acute myeloid leukemia, osteosarcoma, or colon cancer
(reviewed in refs. 2, 3). Similarly, patients with X-linked dys-
keratosis are predisposed to myeloid leukemia and a variety of
solid tumors (4), whereas patients with 5q− syndrome are at
higher risk of developing acute myeloid leukemia (reviewed in
ref. 5). In the genetically tractable zebrafish model, heterozygous
loss-of-function mutations in several ribosomal proteins cause
development of peripheral nerve sheet tumors (6). Somatically
acquired mutations in ribosomal proteins are also implicated in
cancer: ∼10% of children with T-cell acute lymphoblastic leukemia
(T-ALL) were found to harbor somatic mutations in the ribosomal
protein of the large subunit (LSU) 10, 5, and 22 (RPL10, RPL5,
and RPL22) (7). [Note that the proteins encoded by these
genes are also named uL16, uL18, and eL22, respectively,
under the newly proposed uniform ribosomal protein nomen-
clature (8).] A separate study identified heterozygous deletions in
the region of chromosome 1p that contains RPL22 (eL22) in an
additional 10% of patients with T-ALL (9). The model of ri-
bosomal proteins as targets for somatic mutations in cancer is
further supported by the finding that two ribosomal protein genes
(RPL5/uL18 and RPL22/eL22) are included in the list of 127
genes identified as significantly mutated in cancer in the context of
the first Cancer Genome Atlas pan-cancer analysis in 12 tumor
types (10).
Ribosomopathies present an intriguing paradox: Although
patients initially present with hypoproliferative disorders (e.g.,
anemias, bone marrow failure), those who survive to middle age
often develop hyperproliferative diseases (i.e., cancers). The link
between ribosome defects and hypoproliferative disease phe-
notypes has been extensively studied: The current working hy-
pothesis is that impaired ribosome biogenesis activates a
“ribosomal stress” cascade, activating the cellular TP53 pathway
and resulting in cell cycle arrest and cell death (11). However,
activation of TP53 does not explain why ribosomal defects are
associated with hyperproliferative diseases, particularly cancer.
Mutations in the ribosomal protein gene RPL10/uL16 were
recently identified in patients with T-ALL (7). The T-ALL–
associated RPL10/uL16 mutations occurred almost exclusively
in residue arginine 98 (R98), with the exception of one patient
harboring the Q123P mutation, which lies adjacent to R98
within the rpL10/uL16 3D structure (Fig. 1). Both residues are
at the base of an essential flexible loop in rpL10 that closely ap-
proaches the peptidyltransferase center in the catalytic core in the
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ribosome (12). In addition to its role in catalysis (13, 14), rpL10/
uL16 plays an important role in the late stages of 60S subunit
biogenesis. After initial production of the separate ribosomal
subunits in the nucleus, immature and functionally inactive pre-60S
subunits are exported to the cytoplasm, where they undergo ad-
ditional maturation events (15), including incorporation of rpL10/
uL16, before they can associate with mature 40S subunits and
engage in protein synthesis (16). Among the critical set of final 60S
maturation steps is the release of the antiassociation factor Tif6,
followed by release of Nmd3, the primary export adaptor for the
pre-60S subunit in yeast and in humans (17, 18). Tif6 release
requires the tRNA structural mimic Sdo1p (19) and the GTPase
Efl1, a paralog of eukaryotic elongation factor 2 (eEF2) (20). We
have suggested that structural rearrangements of the internal loop
of rpL10/uL16 coordinate this final maturation process, resulting
in a test drive of the pre-60S subunit to ensure that only properly
functioning subunits are allowed to enter the pool of translationally
active ribosomes (13, 21). Defective ribosomes carrying mutations
in rpL10/uL16 specifically fail in this test drive, leading to their
degradation through a molecular pathway that is yet to be char-
acterized. Beyond 60S maturation, rpL10/uL16 plays an important
role in coordinating intersubunit rotation and controlling allosteric
rearrangements within the ribosome, helping to ensure the di-
rectionality and fidelity of protein synthesis (13).
rpL10/uL16 is highly conserved among eukaryotes: The yeast
and human proteins are interchangeable, and residue 98 is
invariantly an arginine (22). Human RPL10/uL16 is located on
the X chromosome, and is therefore expressed as a single-copy
gene in males. Thus, the haploid yeast model is an excellent
mimic of the situation in the cells of a patient with T-ALL. Yeast
cells expressing rpl10-R98S, rpl10-R98C, and rpl10-H123P (cor-
responding to Q123 in human rpL10/uL16) as the sole forms of
rpL10/uL16 displayed proliferative defects. Further, polysome
profiling revealed increased ratios of free 60S and 40S subunits
vs. monosomes, markedly reduced polysomes, and the presence
of halfmers in these mutants, suggesting defects in both ribosome
biogenesis and subunit joining (7). Tif6 and Nmd3 both accu-
mulated in the cytoplasm in the mutant cells, indicating a defect
in their release from the cytoplasmic 60S (7). Thus, all of the
rpl10/uL16 mutations appeared to affect 60S biogenesis at the
Efl1-dependent quality control step. Consistent with the yeast-
based observations, mouse lymphoid cells expressing rpl10-R98S
displayed slower proliferation rates than cells expressing WT
RPL10/uL16 and conferred defective polysome profiles (7).
The studies presented in the current report use the yeast rpl10-
R98S mutant to elucidate the structural, biochemical, and trans-
lational fidelity defects that may lead to carcinogenesis. This
mutant perturbs the structural equilibrium of ribosomes toward
the “rotated state.” At the biochemical level, this underlying
structural defect alters the affinity of mutant ribosomes for
a specific set of trans-acting ligands. In turn, the biochemical
defects affect translational fidelity, promoting elevated rates of
−1 programmed ribosomal frameshifting (−1 PRF) and impaired
recognition of termination codons. Globally increased rates of
−1 PRF result in a decreased abundance of cellular mRNAs that
harbor operational −1 PRF signals (23, 24). These −1 PRF
signal-containing mRNAs include EST1, EST2, STN1, and
CDC13, which play central roles in yeast telomere maintenance
(23). In rpl10-R98S cells, the steady-state abundances of these
mRNAs are decreased, resulting in telomere shortening. A
spontaneously acquired trans-acting mutant suppresses the ri-
bosome biogenesis defects of the rpl10-R98S mutant, thereby
reestablishing high levels of ribosome production and cell pro-
liferation. Importantly, however, suppression of the biogenesis
and growth impairment defects fails to suppress the profound
structural, biochemical, and translational fidelity defects of rpL10-
R98S ribosomes. These findings suggest that suppression of the
growth defect results from bypassing the test drive. Although the
suppressor mutation enables cells to grow at normal rates, genetic
suppression comes at the cost of releasing functionally defective
ribosomes into the translationally active pool. We propose two
different but not mutually exclusive models for how somatically
acquired rpL10/uL16 mutations may promote cancer: (i) Mutant
ribosomes may drive altered gene expression programs, promoting
T-ALL, or (ii) the suppressor mutations may themselves be the
drivers of T-ALL.
Results
The rpl10-R98S Proliferation and Biogenesis Defects Are Suppressed
by the NMD3-Y379D Mutant.We previously showed that the rpl10-
R98S mutation severely impairs growth in yeast (7). However, we
have noted that yeast cells carrying the rpl10-R98S mutation
readily acquire suppressing mutations that compensate for the
growth defect. Sequence analyses identified a mutation in the
export adapter NMD3, NMD3-Y379D, which suppresses both
the growth (Fig. 2A) and the ribosome biogenesis defects (Fig. 2B)
of rpl10-R98S cells. NMD3-Y379D was identified as a dominant
extragenic suppressor of the rpl10-R98S defect. Additionally, an-
euploidy for chromosome VIII-bearing NMD3 was identified as
able to dominantly suppress the rpl10-R98S defect, as is increased
gene dosage of NMD3 (Fig. 2).
The rpl10/uL16-R98SMutation Alters Ribosome Rotational Status, and
This Defect Is Not Suppressed by Coexpression of NMD3-Y379D. As
revealed by extensive rRNA chemical modification analyses, the
internal loop of rpL10 is a central driver of ribosomal rotation
(13). In the current study, analysis of the landmark B7a inter-
subunit bridge was used to monitor the rotational status of the
mutant ribosomes. This universally conserved bridge is formed
by the interaction between A2207 (Escherichia coli A1847) in the
LSU rRNA and G913 (E. coli A702) in the small ribosomal
subunit (SSU) rRNA in the nonrotated state. This interaction is
disrupted upon rotation, rendering both bases susceptible to
chemical modification. WT salt-washed, empty ribosomes are
distributed in an ∼50:50 equilibrium between these two rota-
tional states (25). To monitor the effects of the R98S mutation
on ribosome rotational status, 1-methyl-7-nitroisatoic anhydride
(1M7) was used to probe A2207 of the LSU side of the B7a
intersubunit bridge in purified empty isogenic WT and mutant
ribosomes, as well as in fully rotated and nonrotated WT ribo-
some controls. The extent to which these bases were modified
was quantitatively assessed and normalized using high-through-
put selective 2′-hydroxyl acylation analyzed by primer extension
(hSHAPE) (26, 27). The increased reactivity of A2207 to 1M7
(area under the peaks) reveals that rpL10-R98S ribosomes shift
the structural equilibrium toward the rotated state (Fig. 3A).
Importantly, this rotational disequilibrium is not suppressed by
coexpression of NMD3-Y379.
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Fig. 1. Localization of rpL10 and the loop in the LSU. (A) rpL10/uL16 in the
context of the crown view of the LSU. (B) Close-up view of rpL10/uL16 and
the local environment. The flexible loop structure is indicated by dashed red
lines, and the positions of R98 and Q123 are indicated. rpL10/uL16 is situated
between helices 38 and 89, and it is located in close proximity to several
functional centers of the LSU, including the peptidyltransferase center (PTC),
aa-tRNA accommodation corridor, and elongation factor binding site. Images
were generated using PyMOL.
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The rpl10-R98S Mutation Alters Ribosomal Affinity for Specific
Ligands, and This Defect Is Not Suppressed by Coexpression of
NMD3-Y379D. Recruitment of trans-acting factors to the ribo-
some is influenced by its rotational status, and other rpl10/uL16
mutants that perturb ribosome rotation alter the steady-state
binding affinities for these factors (13). Similarly, rpL10/uL16-
R98S ribosomes promoted approximately threefold lower affinity
for elongation ternary complex ([14C]-Phe-tRNAPhe•eEF1A•GTP)
and approximately threefold increased affinity for eEF2, both of
which are ligands that specifically interact with the ribosomal A-site
(Fig. 3B and Fig. S1). Comparable to other rpL10/uL16 loop
mutants, rpL10/uL16-R98S ribosomes did not affect binding of
the model P-site ligand, acetylated-[14C]Phe-tRNAPhe (Ac-aa-
tRNA), to the ribosomal P-site. However, akin to other rpl10/
uL16 mutants, R98S mutant ribosomes had an ∼2.5-fold lower
affinity for Sdo1p, a ligand also previously shown to bind at the
ribosomal P-site (13). Notably, none of these biochemical defects
was suppressed by expression of NMD3-Y379D (Fig. 3B). This
finding indicates that although NMD3-Y379D can suppress the
ribosome biogenesis defect, it does not correct the altered ri-
bosomal ligand affinity conferred by the rpl10-R98S mutation.
Thus, the effects of the R98S mutant on ribosome biogenesis can
be separated from the effects on ribosome biochemistry.
Translational Fidelity Defects of the rpl10-R98S Mutant Are Not
Suppressed by NMD3-Y379D. In general, ribosomes must main-
tain a translational reading frame to translate the genetic code
faithfully. However, there are a growing number of examples
of cis-acting mRNA sequences that direct elongating ribosomes
to shift the reading frame: This is called PRF (28). Different
classes of elements can direct ribosomes to slip by one base in either
the 5′ (−) or 3′ (+) direction (−1 PRF and +1 PRF, respectively).
Numerous studies have revealed mechanistic differences between
the two: Most −1 PRF events require slippage of both the A- and P-
site tRNA, whereas only the P-site tRNA is involved in +1 PRF,
directed by the yeast Ty1 and Ty3 retrotransposable elements
(28). Consistent with the biochemical data indicating a large
subunit A-site–specific tRNA binding defect, the rpL10-R98S
mutation stimulated −1 PRF by ∼2.6-fold, whereas +1 PRF
remained unchanged (Fig. S2A). Termination codon recognition,
which requires efficient recruitment of the eRF1/eRF3 complex
to the ribosomal A-site (29), was also compromised in rpl10-
R98S cells (an approximately twofold increase) (Fig. S2B). Dis-
crimination between sense and missense tRNAs during elonga-
tion, a process that occurs in the A-site of the small subunit, was
only slightly affected in rpl10-R98S mutant cells. Consistent with
the structural and biochemical findings, coexpression of NMD3-
Y379D did not suppress either the −1 PRF or termination codon
misreading defects (Fig. S2). To determine whether or not these
genetic and biochemical trends were unique to the R98S mu-
tant, we assayed the effects of a second trans-acting suppressor
of a different rpl10 mutant that exhibits similar phenotypic,
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Fig. 2. (A) Overexpression of NMD3 or coexpression of NMD3-Y379D sup-
presses the rpl10-R98S growth defect. A 10-fold dilution spot assay of iso-
genic strains demonstrates that the rpl10-R98S growth defect is suppressed
by ectopic expression of NMD3 and by the NMD3-Y379D mutation. (B)
Overexpression of NMD3 or coexpression of NMD3-Y379D suppresses the
rpl10-R98S biogenesis defect. Sucrose density gradient analysis. Indicated
strains were grown in glucose to repress genomic RPL10/uL16 for 6 h before
cells were harvested. Extracts were prepared, and nine A260 units were
sedimented through 7–47% sucrose gradients.
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Fig. 3. (A) Coexpression of NMD3-Y379D does not suppress the rpl10-R98S
rotational defect. Reactivity peaks obtained by hSHAPE after probing of the
landmark base A2207 (arrows) at the LSU side of the B7a intersubunit bridge
with 1M7. The control ribosomes were assembled as previously reported (13,
54). The nonrotated control is empty WT ribosomes containing Ac-aa-tRNA
in the P-site. The rotated control is empty WT ribosomes containing deacy-
lated tRNAPhe + eEF2-5’-guanyl-imidodiphosphate (GDPNP). (B) Coexpression
of NMD3-Y379D does not suppress the rpl10-R98S biochemical defects.
Steady-state binding of indicated ligands to ribosomes isolated from cells
expressing WT, rpl10-R98S, and rpl10-R98S + NMD3-Y379D. Dissociation
constants were obtained from binding assays of elongation ternary complex
to the A-site and Ac-aa-tRNA to the P-site as monitored by filter binding.
Sdo1p binding was monitored by measuring levels of [32P]-labeled Sdo1
associated with ribosomes, and eEF2 binding was monitored by the extent
of [14C]-ADP ribosylation of unbound protein. Bars indicate SEM (n = 4). *P <
0.05; **P < 0.01.
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biochemical, and functional defects. Similar to the results de-
scribed above, the TIF6-V192F mutant suppressed the growth
and biogenesis defects of rpl10-S104D mutant cells (13) but did
not suppress the ternary complex binding or −1 PRF defects
(Fig. S3).
Translational Fidelity Defects of the rpl10-R98S Mutant Affect Yeast
Telomere Maintenance. Computational analyses suggest that ∼10%
of eukaryotic cellular mRNAs harbor operational −1 PRF signals
(30). Over 95% of these frameshift events are predicted to func-
tion as mRNA destabilizing elements through the nonsense-
mediated mRNA decay pathway by directing translating ribosomes
to premature termination codons (31). More recently, −1 PRF was
implicated in telomere maintenance in yeast (23). The effects of
the rpl10-R98S mutant on −1 PRF directed by sequences located
in the yeast EST1, EST2, STN1, and CDC13 mRNAs were
quantitatively monitored in live cells using dual-luciferase
reporter–based assays. In rpl10-R98S cells, rates of −1 PRF pro-
moted by all of these cis-acting elements were uniformly enhanced
approximately twofold to threefold and, consistent with the bio-
chemical findings, NMD3-Y379D did not suppress these −1 PRF
defects (Fig. 4A). Similar to results observed with other yeast
mutants that promote globally increased rates of −1 PRF (23), the
steady-state abundances of endogenous EST1, EST2, STN1, and
CDC13 mRNAs were significantly reduced in rpl10-R98S cells as
monitored by quantitative RT-PCR (Fig. 4B). Consistent with −1
PRF data, the NMD3-Y379D mutant did not suppress the effects
of the rpl10-R98S mutant on the abundance of these mRNAs. A
quantitative PCR analysis revealed that the yeast telomeric DNA
repeat sequence was ∼25% less abundant in rpl10-R98S cells,
suggestive of a telomere maintenance defect (Fig. 4C). Coex-
pression of NMD3-Y379D did not correct this telomere defect,
consistent with the inability of this mutation to suppress the bio-
chemical and translational fidelity defects of the rpl10-R98S mu-
tation (Fig. 4C).
Discussion
Although defects in the translational machinery have previously
been linked to cancer, the concept that somatic cells can acquire
a defect in the ribosome machinery is relatively novel and there
is currently little knowledge regarding the molecular mechanisms
by which such a defect may promote (a specific type of) cancer.
In particular, how a mutation like rpl10-R98S, which has a neg-
ative impact on cell growth, can promote a hyperproliferative
disease presents a paradox.
Because rpL10/uL16 is an essential ribosomal protein, we
reasoned that a first step in identifying the role of the rpl10-R98S
mutation in leukemia development should require an in-depth
characterization of the effects of the mutant protein on the
ribosome. Whereas we previously showed that fewer mature
ribosomes are present in rpl10-R98S cells (due to the ribosome
biogenesis defect) (7), the current study reveals that this muta-
tion also has a severe impact on ribosomes at both the structural
and functional levels by causing malfunction of the rpL10 in-
ternal loop. Although previously described mutations that shift
the rotational equilibrium were located at the tip of the loop
(13), the T-ALL mutations localize at its base, possibly changing
the general flexibility and dynamic nature of the loop, and thus
its ability to influence ribosomal rotational status. We document
in this work that the rpl10/uL16-R98Smutation impairs aa-tRNA
binding to the A-site and Sdo1p at the P-site, that it increases
affinity for eEF2, and that it decreases the fidelity of the A-site–
associated aspects of protein translation.
Previously, we showed that NMD3 overexpression partially
rescued the proliferation defect observed in rpl10-R98S cells (7).
Here, we demonstrate that the spontaneous suppressor NMD3-
Y379D also compensates for the proliferation and ribosome
biogenesis defects of rpl10-R98S. Importantly, the coexpression
of NMD-Y379D only suppressed the ribosome biogenesis and
proliferation defects of rpl10-R98S cells but did not alter the
intrinsic structural and biochemical defects of rpL10/uL16-R98S
mutant ribosomes. Similarly, a different suppressor, TIF6-V192F,
is able to suppress the ribosome biogenesis defect conferred by
the rpl10-S104Dmutant but did not affect any of the downstream
translation-associated functions. These findings suggest a “selec-
tive pressure”-based model of the connection between riboso-
mopathies and carcinogenesis (Fig. 5). Given the importance of
rpL10 in cytoplasmic maturation of the LSU, mutations in this
protein lead to accumulation of defective pre-60S subunits in
the cytoplasm. Many of these subunits fail the Efl1- and Sdo1-
dependent test drive (21) and are likely removed by the non-
functional ribosome decay (NRD) apparatus. The resulting
dearth of 60S subunits explains the hypoproliferation phenotype
caused by expression of rpL10-R98S. We suggest that this 60S
subunit deficit also exerts pressure on cell populations to select
for mutations that suppress the biogenesis defects or otherwise
bypass NRD. Such suppressors could subvert the quality control
mechanisms and serve to increase the abundance of 60S sub-
units, reversing the proliferation defect. However, such sup-
pression comes at the risk of allowing cells to use defective
ribosomes. The use of such defective ribosomes in translation
ultimately drives altered gene expression patterns, as evidenced,
in part, by decreased abundances of −1 PRF signal-containing
mRNAs. In yeast, cellular −1 PRF signal containing mRNAs
include four that encode proteins implicated in telomere main-
tenance. Although we have used telomere maintenance to il-
lustrate how defects in ribosome function can lead to altered
gene expression, we anticipate that other pathways are also af-
fected in yeast. Studies in bacteria have identified an un-
expectedly large number and diversity of recoding events (32–
34), suggesting that such recoding is pervasive in biology.
Although we have demonstrated that ∼10% of mammalian
mRNAs harbor strong candidate −1 PRF signals, our studies
also show that this class of cis-acting mRNA elements evolves
quickly and does not appear to be well conserved (30). Thus,
identifying the critical pathways that are misregulated in T-ALL
is a remaining challenge. In sum, the analysis presented here
illuminates a pathway from genotype to phenotype, and we
suggest that suppression of the ribosome biogenesis defects
represents a critical event in the progression of these cells to T-ALL.
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A B C Fig. 4. Coexpression of NMD3-Y379D does not sup-
press the rpl10-R98S telomere maintenance defects.
(A) The −1 PRF directed by sequences in the following
yeast genes: EST1 (signal beginning at nucleotide 1,272),
EST2 (signal beginning at nucleotide 1,251), STN1 (signal
beginning at nucleotide 1,203), and CDC13 (signal be-
ginning at nucleotide 1,272). (B) Expression of endoge-
nous EST1, EST2, STN1, and CDC13 mRNAs was moni-
tored by quantitative RT-PCR. Bars indicate SEM (n = 4).
(C) Coexpression ofNMD3-Y379D does not suppress the
rpl10-R98S telomere length defects. The abundance of
telomere repeat sequences was quantified by PCR, with
the single-copy reference gene SGS1 as the loading
control. Bars indicate SEM (n = 9). *P < 0.05; **P < 0.01.
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While providing a temporary fix by bypassing the primary quality
checkpoint in ribosome assembly, suppressing mutations that
reduce translational fidelity are ultimately themselves the drivers
of disease because they directly promote altered cellular gene
expression programs by enhancing utilization of endogenous
“error-prone” sites (i.e., those that promote frameshifting and
termination codon read-through). As such, endogenous error-
prone sites may be of general importance for other “later life”
phenotypes involving impaired cellular homeostasis.
The ribosome biogenesis pathways are highly conserved from
yeast to humans, begging the question of what kinds of ribosome
biogenesis defects may render cells more prone to this transition
from hypo- to hyperproliferative growth states. It is reasonable to
suppose that the list of ribosomal protein mutants that could pro-
mote such a transition would be limited to those mutants involved
in late stages of subunit maturation. This is because proteins in-
volved in early stages of LSU biogenesis are more likely to be re-
quired for the overall structural integrity of the subunit and
mutations in such proteins would not be tolerated. Although anal-
ysis of ribosomal protein genes linked to known ribosomopathies
that affect LSU biogenesis is consistent with this idea, this trend
does not apply to those involved in SSU biogenesis (Fig. S4A).
Inspection of yeast atomic resolution structures reveals that the
ribosomopathy linked ribosomal proteins are all globular proteins
located on the cytoplasmic/solvent-accessible surfaces of the sub-
units (35) (Fig. S4 B and C). These types of proteins are not in-
volved in stabilizing interdomain rRNA interactions and are not
located in regions of the ribosome directly associated with the
central functions of mRNA decoding and peptidyl transfer. Thus,
this structural analysis suggests that only those mutants that allow
a ribosomal subunit to become mature enough to engage the
translational apparatus yet still allow sufficient perturbations of
gene expression fall into the category of ribosomopathogenic pro-
teins. The two trans-acting factors linked to ribosomopathies, SBDS
(Shwachman–Bodian–Diamond syndrome protein) and DKC1
(dyskerin), are also consistent with this theory: SBDS is involved in
the late, cytoplasmic test drive of pre-60S subunits (36), and rRNA
modifications, although occurring early during rRNA transcription,
merely “fine-tune” ribosome structure rather than play central roles
in domain folding (37–39). Given the large numbers of small nu-
cleolar ribonuclear particles (snoRNPs) (and the snoRNAs and
proteins that constitute them) involved in rRNA modification, plus
the scores of other protein factors involved in ribosome biogenesis,
it is conceivable that this model of ribosome-based transition
from hypoproliferative to hyperproliferative growth may be more
widespread than previously appreciated.
The next phase of research will be to determine the nature
of compensatory mutations that may be occurring in human RPL10/
uL16-R98S T-ALL cells. Studies in our laboratories using cells
derived from patients with RPL10/uL16-R98S T-ALL have not
uncovered point mutations or copy number changes affecting late
60S biogenesis factors, such as NMD3, EIF6, SBDS, EFTUD1, or
LSG1. This is not an exhaustive list of ribosome biogenesis factors:
Recent results indicate that mammalian cells may have additional
proteins involved in ribosome biogenesis (40). Mutations in other
biological pathways downstream of the primary defect could also
potentially prevent defective ribosomes from freely entering the
translationally active pool. For example, the still poorly understood
NRD pathway lies genetically downstream of the pre-60S test drive
(41). Mutants in this process would be expected to enable defective
ribosomes similarly to enter the translational pool. Moreover, sup-
pressing mutations by themselves may promote cellular transforma-
tion by yet other mechanisms.
In this work, we focused on the role of rpL10/uL16 on ribosomal
function. Mammalian ribosomal proteins have also been shown
to have functions independent of protein translation, however
[reviewed in (42, 43)]. In particular, RPL10/uL16 has been linked to
regulation of the oncogenic transcription factor JUN (44) and the
V-Yes-1 Yamaguchi sarcoma viral oncogene homolog 1 (45). It is
possible that alteration of one of these or of additional unknown
“extraribosomal” functions of RPL10/uL16 may also contribute to
the pathological role of RPL10/uL16-R98S. Although such alter-
native explanations remain important subjects for investigation, the
findings presented in the current work support that RPL10/uL16-
R98S promotes defective translational fidelity. The role of these
defects in oncogenesis should now be explored.
Materials and Methods
Media, Strains, Plasmids, and Genetic Manipulation. E. coli DH5 alpha was used
to amplify plasmid DNA. Transformation of E. coli and yeast and preparation
of yeast growth media (YPAD = 1% Bacto yeast extract, 2% Bacto peptone,
2% glucose, 0.004% adenine sulfate, and synthetic dropout medium) were as
reported earlier (46, 47). Restriction enzymes were obtained from Promega
and Roche Applied Science. DNA sequencing was performed by Genewiz.
The haploid Saccharomyces cerevisiae strain AJY1437 (MATα rpl10::KanMX
lysΔ0 met15Δ0 leu2Δ0 ura3Δ0 his3Δ0) containing WT RPL10/uL16 on a cen-
tromeric URA3 vector (pAJ392) has previously been described (21). In AJY3222,
the WT vector was replaced by WT RPL10/uL16 on a centromeric LEU2 vector
(pAJ2522) through standard 5-fluoroorotic acid shuffling techniques (48).
AJY3209 harbors pAJ2609, a centromeric LEU2 vector expressing the rpl10-
S104D allele. Similarly, AJY2784 contains pAJ2726, which expresses the rpl10-
R98S mutant from a centromeric LEU2 vector. Identification of suppressing
mutations has previously been described (21). In suppression studies, AJY3209
was transformed with pAJ2240, which expresses TIF6-V192F from a centro-
meric URA3 vector; AJY2784 was transformed with pAJ2805, which expresses
NMD3-Y379D from a centromeric URA3 vector. Dilution spot assays were
performed by growing yeast to midlog growth phase in liquid culture and
spotting them in 10-fold serial dilutions from 105 to 101 cfu per spot on ap-
propriate media, followed by a 2-d incubation at 30 °C or as appropriate.
Translational Fidelity and Polysome Analyses. Standard dual-luciferase re-
porter plasmids were used to monitor −1 PRF, +1 PRF, suppression of UAA,
and suppression of an AGC near-cognate serine codon in place of the cog-
nate AGA codon in the firefly luciferase catalytic site, as previously described
(49–51). The reporters were expressed from high-copy URA3/LEU2-based
plasmids (pJD375, pJD376, pJD376, pJD431, pJD642, and pJD643), and sam-
ple readings were collected using a GloMax Multi-Microplate luminometer
(Promega). Sucrose density gradient analysis was carried out as described (21).
Ribosome Biochemistry and Structural Probing. Purification of active 80S
ribosomes using cysteine-charged sulfolink columns was performed as de-
scribed (13). eEF1A preparation, purification of aminoacyl-tRNA synthetases,
charging of tRNAPhe (Sigma) with [14C]-phenylalanine (PerkinElmer), and
purification of aminoacyl-tRNA and acetylated aminoacyl-tRNA were carried
out as described (52, 53). Filter binding assays to determine steady-state
dissociation rates (Kds) of [
14C]-Phe-tRNAPhe•eEF1A•GTP to the ribosomal
A-site and Ac-[14C]-Phe-tRNAPhe to the ribosomal P-site were performed as
described (13). The Kds obtained from binding assays of eEF2, as monitored
by extent of [14C]-ADP ribosylation of unbound protein, and [32P]-Sdo1p, as
L10/uL16
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Fig. 5. Model of T-ALL progression. A mutation in RPL10/uL16 results in the
inability of the pre-60S subunits to pass the quality control checkpoint,
leading to decreased ribosome assembly and proliferation. A ribosome
biogenesis suppressor can arise due to selective pressure allowing the bypass
the quality test drive, thereby boosting production of defective ribosomes.
Continued defective translation ultimately leads to an altered gene expres-
sion profile and the onset of T-ALL.
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monitored by levels of radiolabel incorporation in ribosomes, were as de-
scribed (13). Kd values were calculated using GraphPad Prism software fitted
to a single binding site with ligand depletion models. rRNA structural
probing experiments of the landmark B7a intersubunit bridge with 1M7
were performed as recently described using hSHAPE and primer 2632 (13).
To prepare “nonrotated” control ribosomes, empty WT 80S ribosomes were
incubated with N-acetyl-phenylalanyl tRNAPhe. To prepare “rotated” control
ribosomes, empty WT 80S ribosomes were first incubated with deacylated
tRNAPhe, followed by eEF2 and GDPNP as described (13, 54).
mRNA Abundance and Telomere Length Analyses. Quantitative PCR experiments
to assay mRNA abundance were carried out as described (23). Similar methods
were used to quantify telomere length in yeast cells. Genomic DNAwas isolated
from midlogarithmic cell cultures using the “smash and grab” yeast DNA
preparation method as described (55). Each DNA sample was diluted serially.
Quantitative polymerase chain reactions to determine yeast telomere content
(T) relative to the single-copy reference gene SGS1 (S) were performed using
the Bio-Rad iTaqTM Universal SYBR Green system utilizing primer pairs com-
plementary to telomere repeats (listed in Table S1), and cycle threshold values
were determined. The T/S ratios were calculated from three experimental
replicates at each of three DNA concentrations (100, 200, and 400 ng). The
Student t test for two-tailed P value calculations was used throughout.
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